A Prospective, Multi-center, Randomized Trial Comparing Statin with Calcium Channel Blocker to Mineralocorticoid Receptor Antagonist with Calcium Channel Blocker in Primary Aldosteronism Treatment

What this Trial Is About

Researchers are evaluating treatments for primary aldosteronism (PA), a condition with limited drug options that affect long-term heart health. This phase 4, randomized trial plans to study three different drug combinations to observe their effects on blood hormone levels, blood pressure, and cardiovascular risks over time. Participants will be randomly assigned to one of three groups: one receiving Simvastatin combined with Amlodipine besylate, another receiving Simvastatin combined with Spironolactone and Amlodipine besylate, and the last receiving Amlodipine besylate combined with Spironolactone. Each treatment will last for six months, allowing comparison of how these combinations influence plasma aldosterone, urinary aldosterone, and other health measures. During the study, participants will have their blood hormone levels, blood pressure, potassium, renin, cholesterol, and glucose monitored at six months. These assessments help determine changes related to the treatments and the ongoing cardiovascular risk. The study will run until September 2026, with careful monitoring to track patient health and treatment response throughout the six-month treatment period.

Statin Combined with Amlodipine Treats Primary Aldosteronism